Patents Assigned to QuiaPEG Pharmaceuticals AB
  • Releasable GLP-1 conjugates
    Patent number: 11957735
    Abstract: The present application provides compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein D is a residue of a GLP-polypeptide or an analog thereof, which underdo hydrolysis under physiological conditions to release the GLP-polypeptide or analog thereof and which are useful in the treatment of disorders that could be beneficially treated with the GLP-polypeptide or analog thereof.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: April 16, 2024
    Assignee: QuiaPEG Pharmaceuticals AB
    Inventors: Marek Kwiatkowski, Christian Sund
  • Releasable conjugates
    Patent number: 11786599
    Abstract: The present application provides compounds of Formula (B): or pharmaceutically acceptable salts thereof, wherein D is a residue of a biologically active drug, which underdo hydrolysis under physiological conditions to release the biologically active drug and which are useful in the treatment of disorders that could be beneficially treated with the drug.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: October 17, 2023
    Assignee: QuiaPEG Pharmaceuticals AB
    Inventors: Marek Kwiatkowski, Christian Sund
  • Functionalized polymers
    Patent number: 11773219
    Abstract: This document relates to functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such functionalized polymers.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: October 3, 2023
    Assignee: QuiaPEG Pharmaceuticals AB
    Inventor: Marek Kwiatkowski
  • Conjugates of tumor necrosis factor inhibitors to functionalized polymers
    Patent number: 11723981
    Abstract: This document relates to conjugates of TNF inhibitors or derivatives thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.
    Type: Grant
    Filed: June 8, 2022
    Date of Patent: August 15, 2023
    Assignee: QuiaPEG Pharmaceuticals AB
    Inventor: Marek Kwiatkowski
  • Conjugates of biologically active molecules to functionalized polymers
    Patent number: 11510989
    Abstract: This document relates to conjugates of a biologically active molecule or a derivative thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: November 29, 2022
    Assignee: QuiaPEG Pharmaceuticals AB
    Inventor: Marek Kwiatkowski
  • Conjugates of tumor necrosis factor inhibitors to functionalized polymers
    Patent number: 11382984
    Abstract: This document relates to conjugates of TNF inhibitors or derivatives thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: July 12, 2022
    Assignee: QUIAPEG PHARMACEUTICALS AB
    Inventor: Marek Kwiatkowski
  • Releasable GLP-1 conjugates
    Patent number: 11357828
    Abstract: The present application provides compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein D is a residue of a GLP-polypeptide or an analog thereof, which underdo hydrolysis under physiological conditions to release the GLP-polypeptide or analog thereof and which are useful in the treatment of disorders that could be beneficially treated with the GLP-polypeptide or analog thereof.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: June 14, 2022
    Assignee: QuiaPEG Pharmaceuticals AB
    Inventors: Marek Kwiatkowski, Christian Sund
  • Conjugates of tumor necrosis factor inhibitors to functionalized polymers
    Patent number: 10973921
    Abstract: This document relates to conjugates of TNF inhibitors or derivatives thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: April 13, 2021
    Assignee: QuiaPEG Pharmaceuticals AB
    Inventor: Marek Kwiatkowski
  • Conjugates of biologically active molecules to functionalized polymers
    Patent number: 10806796
    Abstract: This document relates to conjugates of a biologically active molecule or a derivative thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: October 20, 2020
    Assignee: QuiaPEG Pharmaceuticals AB
    Inventor: Marek Kwiatkowski
  • Functionalized polymers
    Patent number: 10781286
    Abstract: This document relates to functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such functionalized polymers.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: September 22, 2020
    Assignee: QuiaPEG Pharmaceuticals AB
    Inventor: Marek Kwiatkowski
  • Conjugates of tumor necrosis factor inhibitors to functionalized polymers
    Patent number: 10653788
    Abstract: This document relates to conjugates of TNF inhibitors or derivatives thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: May 19, 2020
    Assignee: QuiaPEG Pharmaceuticals AB
    Inventor: Marek Kwiatkowski
  • Conjugates of biologically active molecules to functionalized polymers
    Patent number: 10383946
    Abstract: This document relates to conjugates of a biologically active molecule or a derivative thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: August 20, 2019
    Assignee: QuiaPEG Pharmaceuticals AB
    Inventor: Marek Kwiatkowski
  • Conjugates of tumor necrosis factor inhibitors to functionalized polymers
    Patent number: 10207007
    Abstract: This document relates to conjugates of TNF inhibitors or derivatives thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: February 19, 2019
    Assignee: QuiaPEG Pharmaceuticals AB
    Inventor: Marek Kwiatkowski
  • Functionalized polymers
    Patent number: 10125220
    Abstract: This document relates to functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such functionalized polymers.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: November 13, 2018
    Assignee: QuiaPEG Pharmaceuticals AB
    Inventor: Marek Kwiatkowski
  • Conjugates of biologically active molecules to functionalized polymers
    Patent number: 10010621
    Abstract: This document relates to conjugates of a biologically active molecule or a derivative thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: July 3, 2018
    Assignee: QuiaPEG Pharmaceuticals AB
    Inventor: Marek Kwiatkowski
  • Conjugates of tumor necrosis factor inhibitors to functionalized polymers
    Patent number: 9849187
    Abstract: This document relates to conjugates of TNF inhibitors or derivatives thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: December 26, 2017
    Assignee: QuiaPEG Pharmaceuticals AB
    Inventor: Marek Kwiatkowski
  • Conjugates of tumor necrosis factor inhibitors to functionalized polymers
    Patent number: 9220789
    Abstract: This document relates to conjugates of TNF inhibitors or derivatives thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: December 29, 2015
    Assignee: QuiaPEG Pharmaceuticals AB
    Inventor: Marek Kwiatkowski